Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
BGSF BGSF Inc
NEE Nextera Energy Inc
PSB-Y PS Business Parks Inc
ADBE Adobe Inc
APWL Advanced Powerline Technologies Inc
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Closing Price
$13.07
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
421,045
0

Biden's approval ratings on the pandemic drop as vaccination push continues

4:14 pm ET October 14, 2021 (MarketWatch)
Print

By Weston Blasi

New polls show Americans are losing trust in Biden's handling of the pandemic -- about 39% of Americans think it will take more than a year from now to return to normal life

Some Americans' trust in President Joe Biden has taken a hit in recent months as many believe that a "return to normal" from the COVID-19 pandemic is not around the corner.

According to a new poll from Axios-Ipsos, 39% of Americans think it will take more than a year from now to return to normal life, compared to just 9% of people who thought that in June.

See also: 'It's not a magic pill': What Merck's antiviral pill could mean for vaccine hesitancy

This trend is in conjunction with a drop in the public's trust in Biden's handling of the pandemic. According to the same poll, 42% of Americans trust Biden a great deal or a fair amount to provide them with accurate COVID information, a 10-percentage point drop from April, and a 16-percentage point drop from Biden's first day in office as president.

"To the extent that he had any kind of warm feelings or optimism in relation to his presidency or benefit of the doubt, perhaps, that people might have been wanting to give to him, that's gone now," said David Barker, the director of the Center for Congressional and Presidential Studies at American University.

While it's true that one poll could be an outlier, an average of polls of Americans' views on Biden's handling of the pandemic paint a similar picture.

According to FiveThirtyEight's polling average, which Biden's overall approval on his handling of the pandemic has dropped from 62.7% in June to 49.6% now.

Biden has routinely pushed for more Americans to take a COVID vaccine from makers like Pfizer (PFE) and BioNTech, Moderna (MRNA), or Johnson & Johnson (JNJ). As of October 13, 76.6% of all Americans age 12 and over have received at least one COVID shot, according to the CDC's vaccine tracker.

See also: Brooklyn Nets decision to bench Kyrie Irving until he's vaccinated could cost him $15 million

The president received a COVID booster shot last month, but told reporters just before he got the shot "boosters are important, but the most important thing we need to do is get more people vaccinated."

-Weston Blasi

	

(END) Dow Jones Newswires

October 14, 2021 16:14 ET (20:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.